Nicole Le Saux
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Le Saux has a total of 327 co-authors. Here are the top co-authors by number of shared publications:
- Joan Louise Robinson
Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada
9 shared publications - Julie A. Bettinger
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada
6 shared publications Jennifer Bowes
Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ontario, Canada
5 shared publications- David Moher
Institute of Health Policy, Management & Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
4 shared publications - David W. Scheifele
Vaccine Evaluation Center, Division of Infectious and Immunological Diseases, Department of Pediatrics, BC Children's Hospital and the University of British Columbia, Vancouver, Canada
4 shared publications Isabelle Viel-Thériault
Département de pédiatrie, Centre Mère-Enfant-Soleil du CHU de Québec, Québec, QC
4 shared publications
Latest Publications
- Open Access
- 29 January 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 31 (3) , 221-227
Management of serious Staphylococcus aureus infections in children: A survey of paediatric infectious diseases physicians in Canada
Objectives: Staphylococcus aureus (SA) infections are a common problem in children and a frequent reason for paediatric infectious diseases (PID) consultation. We sought to describe contemporary practices of Canadian PID physicians for management of serious paediatric SA infections. Methods: We developed and disseminated a national, self-administered, cross-sectional online survey of Canadian PID consultants to assess practice patterns involving the management of serious paediatric SA infections. Results: Thirty-nine of 84 (46%) PID consultants across 14 Canadian children's hospitals completed the survey; 48.7% (n = 19) had been practising for 10 or more years and 92.1% (n = 35) completed their PID training in Canada. For methicillin sensitive SA (MSSA) infections outside the central nervous system, 56.4% (n = 22) of respondents preferred cefazolin. Ceftriaxone/cefotaxime was used as definitive treatment for MSSA by 26.3% (n = 10). Prescribing penicillin for penicillin sensitive SA was divided with 51.3% (n = 20) choosing to use it. Most respondents chose to treat SA bacteremia (SAB) with no focus in immunocompetent children and neonates for 14 days, 89.7% (n = 35) and 92.3% (n = 36), respectively. Variability was observed in the practices of ordering abdominal ultrasounds and echocardiograms for SAB with no focus, and in the transition to oral antibiotics for MSSA bacteremia. Variability was also noted in treating osteoarticular infections with methicillin resistant SA bacteremia, with 56.4% (n = 22) choosing intravenous antibiotics until an appropriate clinical response is observed while others advised a minimum 7 (17.9%, n = 7) or 14 (12.8%, n = 5) day intravenous course. Conclusion: Our study highlights both areas of consistency and variability among Canadian PID physicians in managing serious SA infections in children, emphasizing the need for evidence-based paediatric guidelines and increased inclusion of children in clinical trials.
- 29 January 2026
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 31 (3) , 221-227
Open AccessManagement of serious Staphylococcus aureus infections in children: A survey of paediatric infectious diseases physicians in Canada
Objectives: Staphylococcus aureus (SA) infections are a common problem in children and a frequent reason for paediatric infectious diseases (PID) consultation. We sought to describe contemporary practices of Canadian PID physicians for management of serious paediatric SA infections. Methods: We developed and disseminated a national, self-administered, cross-sectional online survey of Canadian PID consultants to assess practice patterns involving the management of serious paediatric SA infections. Results: Thirty-nine of 84 (46%) PID consultants across 14 Canadian children's hospitals completed the survey; 48.7% (n = 19) had been practising for 10 or more years and 92.1% (n = 35) completed their PID training in Canada. For methicillin sensitive SA (MSSA) infections outside the central nervous system, 56.4% (n = 22) of respondents preferred cefazolin. Ceftriaxone/cefotaxime was used as definitive treatment for MSSA by 26.3% (n = 10). Prescribing penicillin for penicillin sensitive SA was divided with 51.3% (n = 20) choosing to use it. Most respondents chose to treat SA bacteremia (SAB) with no focus in immunocompetent children and neonates for 14 days, 89.7% (n = 35) and 92.3% (n = 36), respectively. Variability was observed in the practices of ordering abdominal ultrasounds and echocardiograms for SAB with no focus, and in the transition to oral antibiotics for MSSA bacteremia. Variability was also noted in treating osteoarticular infections with methicillin resistant SA bacteremia, with 56.4% (n = 22) choosing intravenous antibiotics until an appropriate clinical response is observed while others advised a minimum 7 (17.9%, n = 7) or 14 (12.8%, n = 5) day intravenous course. Conclusion: Our study highlights both areas of consistency and variability among Canadian PID physicians in managing serious SA infections in children, emphasizing the need for evidence-based paediatric guidelines and increased inclusion of children in clinical trials.
- 17 December 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (4) , 276-280
Narrow spectrum, broad utility: Reassessing cephalexin and cefazolin beyond cellulitis
- 17 December 2025
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 10 (4) , 276-280
Narrow spectrum, broad utility: Reassessing cephalexin and cefazolin beyond cellulitis
- 7 October 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 99, 237-240
Cephalexin use in a pediatric emergency department during the shortage of amoxicillin suspension
- 7 October 2025
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 99, 237-240
Cephalexin use in a pediatric emergency department during the shortage of amoxicillin suspension
- Open Access
- 20 September 2024
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 30 (2) , 78-82
Streptococcus pneumoniae-associated hemolytic uremic syndrome Canadian Immunization Monitoring Program ACTive National Pediatric Surveillance (1991 to 2019)
Streptococcus pneumoniae-associated hemolytic uremic syndrome (SP-HUS) is an underreported cause of pediatric atypical HUS. This study describes the epidemiology of the largest Canadian case series of SP-HUS in comparison with non-HUS invasive pneumococcal disease (IPD). The Canadian Immunization Monitoring Program, ACTive (IMPACT) is a national surveillance network for vaccine-preventable diseases. All confirmed IPD cases from 1991 through 2019 were included in the analysis. IPD cases with new HUS diagnoses were identified as SPHUS cases, and the rest as non-HUS IPD. There were 30 (0.4%) cases of SP-HUS amongst 6757 IPD cases. The median age of SP-HUS cases was 27.5 months, with no significant differences between SP-HUS and non-HUS cases in age or sex. Streptococcus pneumoniae serotypes 3 (30%) and 19A (26.7%) were more common in SP-HUS compared to non-HUS (P < 0.0001). Pneumonia was more frequently observed in SPHUS than in non-HUS (67% versus 26%; P < 0.0001). All SP-HUS cases were hospitalized, compared with 71% of non-HUS IPD cases (P = 0.0004). SP-HUS cases had a longer median hospital length of stay than non-HUS (23.5 versus 7 days; P < 0.0001) and a higher proportion required an Intensive Care Unit (ICU) admission (70% versus 15.5%; P < 0.0001). Moreover, ICU stays were longer in HUS cases compared with non-HUS cases (9 versus 3 days; P < 0.0001). All 30 SP-HUS patients survived while 3% of non-HUS cases died (P = 0.33). SP-HUS was usually seen in IPD cases with pneumonia and was most commonly caused by serotypes 3 and 19A. ICU care was lengthy, hospital stay was longer. No deaths occurred among SP-HUS cases.
- 20 September 2024
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 30 (2) , 78-82
Open AccessStreptococcus pneumoniae-associated hemolytic uremic syndrome Canadian Immunization Monitoring Program ACTive National Pediatric Surveillance (1991 to 2019)
Streptococcus pneumoniae-associated hemolytic uremic syndrome (SP-HUS) is an underreported cause of pediatric atypical HUS. This study describes the epidemiology of the largest Canadian case series of SP-HUS in comparison with non-HUS invasive pneumococcal disease (IPD). The Canadian Immunization Monitoring Program, ACTive (IMPACT) is a national surveillance network for vaccine-preventable diseases. All confirmed IPD cases from 1991 through 2019 were included in the analysis. IPD cases with new HUS diagnoses were identified as SPHUS cases, and the rest as non-HUS IPD. There were 30 (0.4%) cases of SP-HUS amongst 6757 IPD cases. The median age of SP-HUS cases was 27.5 months, with no significant differences between SP-HUS and non-HUS cases in age or sex. Streptococcus pneumoniae serotypes 3 (30%) and 19A (26.7%) were more common in SP-HUS compared to non-HUS (P < 0.0001). Pneumonia was more frequently observed in SPHUS than in non-HUS (67% versus 26%; P < 0.0001). All SP-HUS cases were hospitalized, compared with 71% of non-HUS IPD cases (P = 0.0004). SP-HUS cases had a longer median hospital length of stay than non-HUS (23.5 versus 7 days; P < 0.0001) and a higher proportion required an Intensive Care Unit (ICU) admission (70% versus 15.5%; P < 0.0001). Moreover, ICU stays were longer in HUS cases compared with non-HUS cases (9 versus 3 days; P < 0.0001). All 30 SP-HUS patients survived while 3% of non-HUS cases died (P = 0.33). SP-HUS was usually seen in IPD cases with pneumonia and was most commonly caused by serotypes 3 and 19A. ICU care was lengthy, hospital stay was longer. No deaths occurred among SP-HUS cases.
- 29 March 2024
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 9 (1) , 11-19
Finding significant pathogens in blood cultures in children: Should we set the timer to 36 hours?
Background: Knowledge of time to positivity (TTP) for blood cultures is useful to assess timing of discontinuation of empiric antimicrobials for suspected bacteremia with no focus. Methods: An audit of positive blood cultures from the Children’s Hospital of Eastern Ontario (CHEO) from November 1, 2019, to October 31, 2020, was performed to determine TTP, defined as the start of incubation to a positive signal from automated incubators. Results: Three hundred seventy-six positive blood cultures were identified from 248 patients (average age: 6.27 [SD 6.24] years). Of these, 247 isolates were speciated; 90 (36.4%) were definitive/probable (DP) pathogens (median TTP 12.75 hours) and 157 (63.6%) possible/probable (PP) contaminants (median TTP 24.08 hours). At each time point, the adjusted rate of positive blood culture was significantly higher for DP pathogens compared to PP contaminants (hazard ratio [HR] 1.80 [95% CI 1.37, 2.36]) and for children ≤27 days old compared to the oldest age group (HR 1.94 [95% CI 1.19, 3.17]). By 36 hours, the proportion of positive cultures was significantly higher in the youngest age group (≤27 days) compared with the 3–11 years old age group (91.7% [95% CI 68.6%, 97.8%] versus 58.2% [95% CI 46.91%, 68.06%]). Conclusion: Across all ages, the TTP was significantly shorter for blood cultures with DP pathogens compared to those with PP contaminants (HR 1.80 [95% CI 1.37, 2.36]). In newborns, 90% of blood cultures were positive by 36 hours supporting this re-assessment time for empiric antimicrobials. TTP was longer in children ≥12 months, possibly related to other factors such as blood culture volume.
- 29 March 2024
- Published by University of Toronto Press Inc. (UTPress) in Journal of the Association of Medical Microbiology and Infectious Disease Canada
- Vol. 9 (1) , 11-19
Finding significant pathogens in blood cultures in children: Should we set the timer to 36 hours?
Background: Knowledge of time to positivity (TTP) for blood cultures is useful to assess timing of discontinuation of empiric antimicrobials for suspected bacteremia with no focus. Methods: An audit of positive blood cultures from the Children’s Hospital of Eastern Ontario (CHEO) from November 1, 2019, to October 31, 2020, was performed to determine TTP, defined as the start of incubation to a positive signal from automated incubators. Results: Three hundred seventy-six positive blood cultures were identified from 248 patients (average age: 6.27 [SD 6.24] years). Of these, 247 isolates were speciated; 90 (36.4%) were definitive/probable (DP) pathogens (median TTP 12.75 hours) and 157 (63.6%) possible/probable (PP) contaminants (median TTP 24.08 hours). At each time point, the adjusted rate of positive blood culture was significantly higher for DP pathogens compared to PP contaminants (hazard ratio [HR] 1.80 [95% CI 1.37, 2.36]) and for children ≤27 days old compared to the oldest age group (HR 1.94 [95% CI 1.19, 3.17]). By 36 hours, the proportion of positive cultures was significantly higher in the youngest age group (≤27 days) compared with the 3–11 years old age group (91.7% [95% CI 68.6%, 97.8%] versus 58.2% [95% CI 46.91%, 68.06%]). Conclusion: Across all ages, the TTP was significantly shorter for blood cultures with DP pathogens compared to those with PP contaminants (HR 1.80 [95% CI 1.37, 2.36]). In newborns, 90% of blood cultures were positive by 36 hours supporting this re-assessment time for empiric antimicrobials. TTP was longer in children ≥12 months, possibly related to other factors such as blood culture volume.
- Open Access
- 1 November 2023
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 11 (6) , E1156-E1163
The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study
Background: Canadian immunization programs for rotavirus started in 2011. We sought to determine their effect on the burden of community-acquired admissions and hospital-acquired rotavirus at pediatric hospitals. Methods: The Canadian Immunization Monitoring Program Active (IMPACT) network conducted active surveillance for rotavirus-positive hospital admissions between 2005 and 2020 at 12 pediatric hospitals. We used yearly rates of community-acquired rotavirus per 10 000 admissions and hospital-acquired rotavirus infections per 1000 patient-days to determine changes in the pre- and post-vaccine program periods. Results: During the 15-year study period, 5691 rotavirus hospital admissions and hospital-acquired infections were detected, including 4323 (76%) community-acquired infections and 1368 (24%) hospital-acquired infections. The average community-acquired rate in the pre-vaccine period was 60.3 (95% confidence interval [CI] 53.7–68.3) per 10 000 admissions, with a decline to 11.0 (95% CI 7.5–15.1) per 10 000 admissions in the post-vaccine period, resulting in an average reduction of 81.7% (95% CI 74.4%–87.8%). The rate of hospital-acquired rotavirus declined from 0.35 (95% CI 0.29–0.41) per 1000 patient-days in the pre-vaccine period to 0.05 (95% CI 0.03–0.07) per 1000 patient-days in the post-vaccine period, resulting in an 85.3% (95% CI 77.7%–91.9%) average decline. Herd protection was present among children aged 2–16 years. Interpretation: Although start dates of rotavirus vaccine programs across provinces varied, there was around an 80% average decrease in both community-acquired and hospital-acquired rotavirus infections at pediatric hospitals in Canada in the 1- to 9-year interval after implementation of rotavirus vaccine programs. Herd protection is an important aspect of rotavirus vaccines for other children who are not vaccine eligible, and rotavirus vaccines continue to provide important benefits both for children and health care systems.
- 1 November 2023
- Published by CMA Impact Inc. in CMAJ Open
- Vol. 11 (6) , E1156-E1163
Open AccessThe success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study
Background: Canadian immunization programs for rotavirus started in 2011. We sought to determine their effect on the burden of community-acquired admissions and hospital-acquired rotavirus at pediatric hospitals. Methods: The Canadian Immunization Monitoring Program Active (IMPACT) network conducted active surveillance for rotavirus-positive hospital admissions between 2005 and 2020 at 12 pediatric hospitals. We used yearly rates of community-acquired rotavirus per 10 000 admissions and hospital-acquired rotavirus infections per 1000 patient-days to determine changes in the pre- and post-vaccine program periods. Results: During the 15-year study period, 5691 rotavirus hospital admissions and hospital-acquired infections were detected, including 4323 (76%) community-acquired infections and 1368 (24%) hospital-acquired infections. The average community-acquired rate in the pre-vaccine period was 60.3 (95% confidence interval [CI] 53.7–68.3) per 10 000 admissions, with a decline to 11.0 (95% CI 7.5–15.1) per 10 000 admissions in the post-vaccine period, resulting in an average reduction of 81.7% (95% CI 74.4%–87.8%). The rate of hospital-acquired rotavirus declined from 0.35 (95% CI 0.29–0.41) per 1000 patient-days in the pre-vaccine period to 0.05 (95% CI 0.03–0.07) per 1000 patient-days in the post-vaccine period, resulting in an 85.3% (95% CI 77.7%–91.9%) average decline. Herd protection was present among children aged 2–16 years. Interpretation: Although start dates of rotavirus vaccine programs across provinces varied, there was around an 80% average decrease in both community-acquired and hospital-acquired rotavirus infections at pediatric hospitals in Canada in the 1- to 9-year interval after implementation of rotavirus vaccine programs. Herd protection is an important aspect of rotavirus vaccines for other children who are not vaccine eligible, and rotavirus vaccines continue to provide important benefits both for children and health care systems.
- 17 March 2023
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 45 (5) , 329-330
Antibiotic Eye Prophylaxis for Newborns: Using the Topical Erythromycin Shortage as an Opportunity to Reflect on Practice Evolution
- 17 March 2023
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 45 (5) , 329-330
Antibiotic Eye Prophylaxis for Newborns: Using the Topical Erythromycin Shortage as an Opportunity to Reflect on Practice Evolution
- 27 May 2022
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 11 (8) , 357-360
Duration of Antibiotic Therapy and Timing of Shunt Reimplantation in Pediatric CSF Shunt Infections: A Retrospective Multicenter Case Series
In this retrospective multicenter series of 154 children with cerebrospinal fluid shunt infections, the median (interquartile range) duration of antibiotic therapy was 18 (14-26) days. The time to shunt replacement was 14 (10-19) days. Management appeared to potentially differ according to the targeted pathogen and site.
- 27 May 2022
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 11 (8) , 357-360
Duration of Antibiotic Therapy and Timing of Shunt Reimplantation in Pediatric CSF Shunt Infections: A Retrospective Multicenter Case Series
In this retrospective multicenter series of 154 children with cerebrospinal fluid shunt infections, the median (interquartile range) duration of antibiotic therapy was 18 (14-26) days. The time to shunt replacement was 14 (10-19) days. Management appeared to potentially differ according to the targeted pathogen and site.
- 25 February 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (6) , 2535-2539
Infants hospitalized for acute COVID-19: disease severity in a multicenter cohort study
Age is the most important determinant of COVID-19 severity. Infectious disease severity by age is typically J-shaped, with infants and the elderly carrying a high burden of disease. We report on the comparative disease severity between infants and older children in a multicenter retrospective cohort study of children 0 to 17 years old admitted for acute COVID-19 from February 2020 through May 2021 in 17 pediatric hospitals. We compare clinical and laboratory characteristics and estimate the association between age group and disease severity using ordinal logistic regression. We found that infants comprised one-third of cases, but were admitted for a shorter period (median 3 days IQR 2–5 versus 4 days IQR 2–7), had a lower likelihood to have an increased C-reactive protein, and had half the odds of older children of having severe or critical disease (OR 0.50 (95% confidence interval 0.32–0.78)). Conclusion: When compared to older children, there appeared to be a lower threshold to admit infants but their length of stay was shorter and they had lower odds than older children of progressing to severe or critical disease. What is Known: • A small proportion of children infected with SARS-CoV-2 require hospitalization for acute COVID-19 with a subgroup needing specialized intensive care to treat more severe disease. • For most infectious diseases including viral respiratory tract infections, disease severity by age is J-shaped, with infants having more severe disease compared to older children. What is New: • One-third of admitted children for acute COVID-19 during the first 14 months of the pandemic were infants. • Infants had half the odds of older children of having severe or critical disease.
- 25 February 2022
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 181 (6) , 2535-2539
Infants hospitalized for acute COVID-19: disease severity in a multicenter cohort study
Age is the most important determinant of COVID-19 severity. Infectious disease severity by age is typically J-shaped, with infants and the elderly carrying a high burden of disease. We report on the comparative disease severity between infants and older children in a multicenter retrospective cohort study of children 0 to 17 years old admitted for acute COVID-19 from February 2020 through May 2021 in 17 pediatric hospitals. We compare clinical and laboratory characteristics and estimate the association between age group and disease severity using ordinal logistic regression. We found that infants comprised one-third of cases, but were admitted for a shorter period (median 3 days IQR 2–5 versus 4 days IQR 2–7), had a lower likelihood to have an increased C-reactive protein, and had half the odds of older children of having severe or critical disease (OR 0.50 (95% confidence interval 0.32–0.78)). Conclusion: When compared to older children, there appeared to be a lower threshold to admit infants but their length of stay was shorter and they had lower odds than older children of progressing to severe or critical disease. What is Known: • A small proportion of children infected with SARS-CoV-2 require hospitalization for acute COVID-19 with a subgroup needing specialized intensive care to treat more severe disease. • For most infectious diseases including viral respiratory tract infections, disease severity by age is J-shaped, with infants having more severe disease compared to older children. What is New: • One-third of admitted children for acute COVID-19 during the first 14 months of the pandemic were infants. • Infants had half the odds of older children of having severe or critical disease.